<DOC>
	<DOCNO>NCT00185835</DOCNO>
	<brief_summary>To determine safety profile epidermal growth factor receptor ( EGFR ) antagonist , ZD1839 combination cisplatin radiation therapy patient local-regional recurrent squamous cell cancer head neck . To study effect ZD1839 combine either cisplatin radiotherapy signal transduction pathway gene expression tumor cell patient local-regional recurrent squamous cell cancer head neck use micro array analysis tumor sample take time relapse treatment .</brief_summary>
	<brief_title>Cisplatin ZD1839 + Re-Irradiation Recurrent Squamous Cell Cancer Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Patients must pathologically confirm recurrence ( reappearance previously clear ) squamous cell cancer primary upper aerodigestive tract second squamous cell primary ( exclude nasopharynx salivary gland tumor ) . Patients may experience one recurrence long first recurrence occur great equal 6 month follow end prior RT . The recurrence second primary must define bi unidimensional measurement . Recurrence second primary must confine head neck clavicle ( locoregional recurrence ) . The patient must candidate complete surgical resection . The previous irradiation must exceed maximum 75 Gy . The entire tumor volume must include treatment field limit total spinal cord dose 50 Gy ( prior RT anticipate RT ) . Patients must least 6 month prior radiation therapy . Patients may receive prior chemotherapy component primary treatment , recurrent disease . Zubrod performance status 01 . Granulocytes great equal 1500/mm3 , platelet great equal 100,000/mm3 , serum bilirubin less equal 1.5 mg/dl , creatinine le equal 1.5 mg/dl within 2 week prior registration . LFT 's less equal 2 x normal ( SGOT/SGPT/Alkaline Phosphatase ) . If great 2 x normal , liver ultrasound CT require exclude metastasis . If negative metastasis , patient eligible . Must able submit previous radiation record , include simulation portal film , order assure cord tolerance exceed . Patients must sign studyspecific inform consent form prior study entry . Primary nasopharynx salivary gland . Intercurrent medical illness would impair patient tolerance therapy limit survival . A history allergic reaction attribute compound similar chemical biologic composition ZD1839 agent use study . Pregnant nursing woman exclude potential teratogenic effect potential unknown effect nurse newborn .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>